CytomX TherapeuticsCTMX
About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Employees: 121
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $36K | Put options by funds: $5K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
1% more funds holding
Funds holding: 69 [Q3] → 70 (+1) [Q4]
5.84% less ownership
Funds ownership: 65.53% [Q3] → 59.69% (-5.84%) [Q4]
20% less capital invested
Capital invested by funds: $60.4M [Q3] → $48.1M (-$12.3M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CTMX.
Financial journalist opinion
Based on 7 articles about CTMX published over the past 30 days
